CenExel is your partner in navigating the complexities of CNS clinical trials. With specialized expertise, advanced technology, and a network of top-tier Centers of Excellence, we ensure precision and care at every step. Our dedicated team is committed to advancing healthcare, delivering reliable data, and improving patient outcomes. Trust #CenExel to support your most challenging CNS studies. Want to learn more? Visit cenexel.com. #CNS #ClinicalTrials #Neuroscience
CenExel’s Post
More Relevant Posts
-
In the latest article from our neurosciences blog series, Parexel Market Access expert Wyatt Gotbetter highlights recent breakthroughs in disease modification, challenges of accurate diagnosis, the use of surrogate endpoints in reimbursement decisions, and essential strategies and best practices for demonstrating value to payers. Discover the latest insights and strategies for accelerating patient access. Read the full article: https://lnkd.in/ex3auERf #Alzheimers #MarketAccess #Neuroscience #ParexelBiotech
-
Early/Late Phase and Regulatory Strategy, RWE & RWD, Market Access, Logistics at Parexel Biotech
In the latest article from our neurosciences blog series, Parexel Market Access expert Wyatt Gotbetter highlights recent breakthroughs in disease modification, challenges of accurate diagnosis, the use of surrogate endpoints in reimbursement decisions, and essential strategies and best practices for demonstrating value to payers. Discover the latest insights and strategies for accelerating patient access. Read the full article: https://lnkd.in/e8JQnvAT #Alzheimers #MarketAccess #Neuroscience #ParexelBiotech
-
In the latest article from our neurosciences blog series, Parexel Market Access expert Wyatt Gotbetter highlights recent breakthroughs in disease modification, challenges of accurate diagnosis, the use of surrogate endpoints in reimbursement decisions, and essential strategies and best practices for demonstrating value to payers. Discover the latest insights and strategies for accelerating patient access. Read the full article: https://lnkd.in/eTvh8UXv #Alzheimers #MarketAccess #Neuroscience #ParexelBiotech
-
In the latest article from our neurosciences blog series, Parexel Market Access expert Wyatt Gotbetter highlights recent breakthroughs in disease modification, challenges of accurate diagnosis, the use of surrogate endpoints in reimbursement decisions, and essential strategies and best practices for demonstrating value to payers. Discover the latest insights and strategies for accelerating patient access. Read the full article: https://lnkd.in/ewwGkxxV #Alzheimers #MarketAccess #Neuroscience #ParexelBiotech
-
In the latest article from our neurosciences blog series, Parexel Market Access expert Wyatt Gotbetter highlights recent breakthroughs in disease modification, challenges of accurate diagnosis, the use of surrogate endpoints in reimbursement decisions, and essential strategies and best practices for demonstrating value to payers. Discover the latest insights and strategies for accelerating patient access. Read the full article: https://lnkd.in/dPmcPYmt #Alzheimers #MarketAccess #Neuroscience #ParexelBiotech
-
In the latest article from our neurosciences blog series, Parexel Market Access expert Wyatt Gotbetter highlights recent breakthroughs in disease modification, challenges of accurate diagnosis, the use of surrogate endpoints in reimbursement decisions, and essential strategies and best practices for demonstrating value to payers. Discover the latest insights and strategies for accelerating patient access. Read the full article: https://lnkd.in/gmDCiN2W #Alzheimers #MarketAccess #Neuroscience #ParexelBiotech
-
Did you know that brain monitoring in infants has proven to be beneficial for more than just HIE? #aEEG can help the clinician in the NICU in multiple ways with clinical applications including subclinical seizure detection and monitoring during therapeutic hypothermia and more. Learn how aEEG can improve outcomes and prognosticate the future of neonates with this complication of 5️⃣ clinician-led case studies: https://hubs.li/Q028JwnZ0 #neonatologist #brainmonitoring #NICU #brainhealth #neonatology
-
DRG are the first “integration center” on the pain pathways. This is the first level where pharmacological modulation can take place. We offer all the ways (in vitro and in vivo) to investigate the pharmacological properties of your compound on sensory neurons!
🔬 Advancing Pain Research with DRG Cell Recordings Our San Diego platform excels in recording from dorsal root ganglion (DRG) cells, providing essential data for drug development. We specialize in recordings from various tissue sources, including those from larger animals, which are critical for generating data with greater translational relevance. By studying these complex systems, we gain richer insights into pain mechanisms, leading to more accurate predictions of human responses. 🔗 Read more: Discover the full potential of DRG sensory neuron recordings and how they can accelerate your pain drug discovery efforts: https://lnkd.in/eHSkY3bP ✉️ Are you currently studying a compound targeting Pain? Reach out to contact@neuroservices-alliance.com or schedule an introductory meeting with us: https://lnkd.in/eEkM9xDN #Neuroscience #PainResearch #CNS #Electrophysiology #DRG
-
-
Matching top talent to meaningful careers at Parexel #withheart 💜 Recruiting positions for US, Canada and EMEA
In the latest article from our neurosciences blog series, Parexel Market Access expert Wyatt Gotbetter highlights recent breakthroughs in disease modification, challenges of accurate diagnosis, the use of surrogate endpoints in reimbursement decisions, and essential strategies and best practices for demonstrating value to payers. Discover the latest insights and strategies for accelerating patient access. Read the full article: https://lnkd.in/dE_8SkCe #Alzheimers #MarketAccess #Neuroscience #ParexelBiotech
-
Vice President (Technical) | Chemistry, Manufacturing & Controls (CMC) and regulatory affairs consultant | Ex-MHRA regulator | Pharmacist
In the latest article from our neurosciences blog series, Parexel Market Access expert Wyatt Gotbetter highlights recent breakthroughs in disease modification, challenges of accurate diagnosis, the use of surrogate endpoints in reimbursement decisions, and essential strategies and best practices for demonstrating value to payers. Discover the latest insights and strategies for accelerating patient access. Read the full article: https://lnkd.in/ex9HAP4f #Alzheimers #MarketAccess #Neuroscience #ParexelBiotech
